You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
復旦張江(01349.HK):裏葆多相比此前中標價格降價幅度不低於35%
格隆匯 04-30 20:22

格隆匯4月30日丨復旦張江(01349.HK)公吿,集團納米技術平台抗腫瘤藥物鹽酸多柔比星脂質體注射液(商標名:裏葆多)於2009年八月上市銷售,為楷萊(Doxil/Caelyx)的國內首仿藥,是國內外首個納米藥物的仿製藥物。該藥物是一種採用先進的隱形脂質體技術包封,具有被動靶向特性的多柔比星新劑型,它是蒽環類藥物的更新換代產品,在腫瘤治療學上具有提高療效、降低心臟毒性、骨髓抑制以及減少脱髮等優勢。該藥物主要用於與艾滋病相關的卡波氏肉瘤,亦可用於多發性骨髓瘤、乳腺癌和卵巢癌等腫瘤的治療。

2024年度,該藥物銷售收入約為人民幣2.1億元,佔集團全年銷售收入的29%。該藥物(規格:10ml:20mg)於部分省(自治區、直轄市)中標價格區間為3,039.60元/瓶至3,951.95元/瓶,醫療機構全年實際採購量合計為72,118瓶。該藥物上市多年,療效穩定且臨牀反饋良好,擁有較好的市場口碑。

經公司審慎研究,決定自2025年5月1日起按照各省份對於未中選產品的規則和要求,陸續調整、梯度降低該藥物的市場零售價格,相比此前中標價格降價幅度不低於35%。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account